Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion type Assertion NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_head.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion description "[Blockade of either CXCL5 or CXCR2 may be a critical adjunct antiangiogenic therapy against pancreatic cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_provenance.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion evidence source_evidence_literature NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_provenance.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion SIO_000772 21356384 NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_provenance.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion wasDerivedFrom befree-2016 NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_provenance.
- NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_assertion wasGeneratedBy ECO_0000203 NP875669.RAoONj9dVAwMDaDRYS-kBMLeQcw1UGzhm0vwcRNYH2Tvg130_provenance.